Vapotherm, Inc.

OTCPK:VAPO Voorraadrapport

Marktkapitalisatie: US$13.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Vapotherm Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Vapotherm's earnings have been declining at an average annual rate of -10.3%, while the Medical Equipment industry saw earnings growing at 11.4% annually. Revenues have been declining at an average rate of 0.4% per year.

Belangrijke informatie

-10.3%

Groei van de winst

9.4%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie8.9%
Inkomstengroei-0.4%
Rendement op eigen vermogenn/a
Nettomarge-76.7%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Vapotherm announces $23M private placement

Feb 08

Vapotherm GAAP EPS of -$0.98 misses by $0.20, revenue of $13.5M misses by $3.02M

Nov 02

Vapotherm draws downgrade at William Blair after 2Q results

Aug 04

Vapotherm: Out Of Air

May 11

Is Vapotherm (NYSE:VAPO) Using Too Much Debt?

Jan 24
Is Vapotherm (NYSE:VAPO) Using Too Much Debt?

Vapotherm: Hardly Breathing Room

Jul 11

Health Check: How Prudently Does Vapotherm (NYSE:VAPO) Use Debt?

May 10
Health Check: How Prudently Does Vapotherm (NYSE:VAPO) Use Debt?

Vapotherm reports Q1 results

May 05

The Independent Director of Vapotherm, Inc. (NYSE:VAPO), Anthony Arnerich, Just Bought 59% More Shares

Mar 12
The Independent Director of Vapotherm, Inc. (NYSE:VAPO), Anthony Arnerich, Just Bought 59% More Shares

Announcing: Vapotherm (NYSE:VAPO) Stock Increased An Energizing 225% In The Last Year

Mar 11
Announcing: Vapotherm (NYSE:VAPO) Stock Increased An Energizing 225% In The Last Year

Does Vapotherm (NYSE:VAPO) Have A Healthy Balance Sheet?

Jan 19
Does Vapotherm (NYSE:VAPO) Have A Healthy Balance Sheet?

Vapotherm guides Q4 revenue above consensus, ~212% Y/Y growth

Jan 13

Thomas Smith of Vapotherm, Inc. (NYSE:VAPO) Just Spent US$217k On Shares

Dec 14
Thomas Smith of Vapotherm, Inc. (NYSE:VAPO) Just Spent US$217k On Shares

Investors Who Bought Vapotherm (NYSE:VAPO) Shares A Year Ago Are Now Up 132%

Dec 11
Investors Who Bought Vapotherm (NYSE:VAPO) Shares A Year Ago Are Now Up 132%

Vapotherm shares +9% on higher Q4 guidance

Dec 01

Vapotherm: The Game Has Completely Changed

Nov 13

Opbrengsten en kosten

Hoe Vapotherm geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

OTCPK:VAPO Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 2471-544513
31 Mar 2470-554814
31 Dec 2369-585214
30 Sep 2368-695815
30 Jun 2366-816517
31 Mar 2363-1086819
31 Dec 2267-1137520
30 Sep 2270-1108021
30 Jun 2295-988920
31 Mar 22103-729419
31 Dec 21113-609318
30 Sep 21132-589918
30 Jun 21124-579219
31 Mar 21139-489219
31 Dec 20126-528917
30 Sep 2098-477616
30 Jun 2078-476714
31 Mar 2055-526013
31 Dec 1948-515613
30 Sep 1947-515412
30 Jun 1945-485111
31 Mar 1944-474910
31 Dec 1842-43459
30 Sep 1841-39428
30 Jun 1840-37398
31 Mar 1838-33368
31 Dec 1736-31348
31 Dec 1630-23266

Kwaliteitswinsten: VAPO is currently unprofitable.

Groeiende winstmarge: VAPO is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: VAPO is unprofitable, and losses have increased over the past 5 years at a rate of 10.3% per year.

Versnelling van de groei: Unable to compare VAPO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: VAPO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (7.2%).


Rendement op eigen vermogen

Hoge ROE: VAPO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden